Kim, Jeongsoo
Kim, Tae-Jin
Chae, Sehyun
Ha, Hyojeong
Park, Yejin
Park, Sunghee
Yoon, Chul Joo
Lim, Seon Ah
Lee, Hyemin
Kim, Jiyoung
Kim, Jungwon
Im, Kyungtaek
Lee, Kyunghye
Kim, Jeongmin
Kim, Daham
Lee, Eunju
Shin, Min Hwa
Park, Serk In
Rhee, Inmoo
Jung, Keehoon
Lee, Jeewon
Lee, Keun Hwa
Hwang, Daehee
Lee, Kyung-Mi
Funding for this research was provided by:
National Research Foundation of Korea (RS-2023-00225581)
Korea Health Industry Development Institute (HD22C2045)
Article History
Received: 28 September 2023
Accepted: 7 January 2024
First Online: 29 February 2024
Declarations
:
: All animal experiments conducted in this study were carried out in accordance with the guidelines and regulations set forth by the Institutional Animal Care and Use Committee of Korea University, with approval numbers KUIACUC-2019-0101 and KUIACUC-2022-0049.
: JSK and KML are named inventors on a patent for a pharmaceutical composition to prevent or treat cancer-comprising monocytes or macrophages that inhibit CD244 expression or activity as an active ingredient (KR10-2022-0067313, PCT/KR2023/007574).